Patients with myocardial infarction and percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor for at least 6 to 12 months [1,2]. The gene discussed is P2RY12; the disease is myocardial infarction.